NCT06203912View on ClinicalTrials.gov

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 5, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspiration and biopsy

DRUG

Cyclophosphamide

Given IV

DRUG

Dexamethasone

Given PO

PROCEDURE

Echocardiography

Undergo echocardiography

BIOLOGICAL

Isatuximab

Given IV

OTHER

Questionnaire Administration

Ancillary study

BIOLOGICAL

Universal Donor Expanded TGF-beta-imprinted NK Cells

Given IV

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
lead

Elvira Umyarova

OTHER

collaborator

Sanofi

INDUSTRY

NCT06203912 - Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter